Study of CDR132L for heart failure with reduced pumping ability and thickened heart muscle
Treatments studied
Part of Heart & circulation clinical trials.
This trial tests a new medicine called CDR132L to see if it improves heart structure and function in people with heart failure who have a thickened heart muscle and reduced pumping ability. Participants will be randomly assigned to receive either the study drug or a placebo.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 40 and 84 years old
- Have had heart failure symptoms for at least 6 months, need a water pill (diuretic) at least once a week, and have specific symptoms (like shortness of breath or fatigue) at screening
- Be stable on current heart failure medications for at least 45 days before starting the study
- Have an ejection fraction (a measure of how well your heart pumps) below 50%, as confirmed by an ultrasound of your heart
- Have a thickened heart muscle or an enlarged heart chamber, also confirmed by ultrasound
- Have a body mass index (BMI) between 18.5 and 40, and weigh no more than 140 kilograms (about 308 pounds)
- Have a blood test result for NT-proBNP (a marker of heart strain) that is at least 300 pg/mL, or at least 600 pg/mL if you have atrial fibrillation
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental medicine, CDR132L, to see if it can improve heart structure and function in people with a type of heart failure where the heart muscle is thickened. If you have heart failure with normal pumping function and thickened heart walls, this trial may offer access to a new potential treatment.
This study tests an experimental medicine called NNC0537-1482 for people with heart failure. It aims to see if the medicine helps improve symptoms and heart function.
This trial tests a treatment intended to improve how heart muscle cells handle calcium, which may help heart failure symptoms and heart function. It is mainly for people with advanced heart failure and a low pumping strength of the heart.
This study tests an experimental drug called LY3971297 to see if it can help people with chronic heart failure. It aims to find out if the drug is safe and if it improves heart function.
This study measures how well the drug CDR132L enters the blood when injected under the skin, compared to injection into a vein. It is done in healthy volunteers to find the best way to give the drug.
This study tests a heart device (CCM) plus standard medications to see if the combination helps people with a weak heart pump. It's for those whose heart function is low and who still have symptoms despite current treatment.
Hear when a new Heart failure trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.